Found: 4
Select item for more details and to access through your institution.
A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-α administered as a 24-hour weekly infusion schedule in patients with advanced cancer.
- Published in:
- Investigational New Drugs, 2005, v. 23, n. 5, p. 467, doi. 10.1007/s10637-005-2906-0
- By:
- Publication type:
- Article
Preclinical and Phase 1 Assessment of Antisense Oligonucleotide Bepirovirsen in Hepatitis B Virus–Transgenic Mice and Healthy Human Volunteers: Support for Clinical Dose Selection and Evaluation of Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses
- Published in:
- Clinical Pharmacology in Drug Development, 2022, v. 11, n. 10, p. 1191, doi. 10.1002/cpdd.1154
- By:
- Publication type:
- Article
Correlations between preclinical BJAB assay ranking of antisense drugs and clinical trial adverse events.
- Published in:
- CTS: Clinical & Translational Science, 2023, v. 16, n. 4, p. 575, doi. 10.1111/cts.13476
- By:
- Publication type:
- Article
A Phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma.
- Published in:
- 2001
- By:
- Publication type:
- journal article